Jazz Pharma (JAZZ) - Gross Profit Margin

Jazz Pharmaceuticals focuses on the commercialization of therapies for rare oncological and neurological pathologies. The gross margin distribution confirms this model, where the 74.60 level serves as a critical benchmark. A specialized portfolio ensures high returns, although patents limit net income. Narcolepsy treatments, which face a low risk of cheap generics, act as a steady cash cow.
Comprehensive metric breakdowns and analytics for Jazz Pharma (JAZZ)

Fundamental selection of high-quality assets is based on analyzing a business's ability to convert revenue into profit after covering direct production costs. This metric measures cost-of-sales management efficiency, which for Jazz Pharmaceuticals (JAZZ) and its niche monopoly in neurology translates to high margins due to minimal drug production costs, as reflected in the gross profit margin trend.